CHAIRMAN, PRESIDENT AND CEO Lipps Randall A was granted 188,794 shares and covered exercise/tax liability with 18,571 shares, increasing direct ownership by 111% to 323,049 units (SEC Form 4)

$OMCL
Computer Manufacturing
Technology
Get the next $OMCL alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LIPPS RANDALL A

(Last) (First) (Middle)
OMNICELL, INC.
4220 NORTH FREEWAY

(Street)
FORT WORTH TX 76137

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
OMNICELL, INC. [ OMCL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CHAIRMAN, PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
03/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 355,861(1) I In Trust with Wife
Common Stock 8,051(2) I In Trust for Children
Common Stock 03/08/2025 A 188,794(3) A $0 341,620 D
Common Stock 03/08/2025 F 18,571(4) D $36.99 323,049 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares held in trust with Mr. Lipps' wife.
2. Shares held in trust for the benefit of Mr. Lipps' children.
3. Reflects performance-based restricted stock units that were previously granted on February 27, 2024, subject to the Company meeting certain stock performance objectives compared to the S&P 1000 Healthcare Index. On March 8, 2025 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 188,794 performance-based restricted stock units (176% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest in equal quarterly increments once every three months over a three-year period (on each May 15, August 15, November 15, and February 15, respectively).
4. Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units
/s/ Vijay Biligiri Attorney in-Fact, Randall A. Lipps 03/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $OMCL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OMCL

DatePrice TargetRatingAnalyst
10/31/2024$44.00 → $57.00Buy → Neutral
BofA Securities
8/2/2024$26.00 → $39.00Underweight → Equal Weight
Barclays
1/3/2024$33.00Underweight
Barclays
11/3/2023$39.00 → $28.00Underweight → Equal Weight
Wells Fargo
11/3/2023Buy → Neutral
BTIG Research
11/3/2023$70.00 → $39.00Neutral → Overweight
Piper Sandler
10/11/2023Overweight → Sector Weight
KeyBanc Capital Markets
9/26/2023$56.00 → $39.00Underweight
Wells Fargo
More analyst ratings

$OMCL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer

    Medical device, pharmaceutical, and life sciences expert tapped to lead Company's technology strategy and global engineering organization Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250324514095/en/Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, on March 31, 2025. Dr. Genova will lead Omnicell's technology str

    $OMCL
    Computer Manufacturing
    Technology
  • Omnicell Announces Chief Financial Officer Transition

    Company Reiterates First Quarter and Full Year 2025 Guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced that Nchacha Etta will be stepping down from his role as Executive Vice President and Chief Financial Officer, effective September 15, 2025 or until a successor is named. Mr. Etta will continue to serve as Executive Vice President and Chief Financial Officer while Omnicell searches for a new Chief Financial Officer and will work to ensure a smooth transition of his role and responsibilities. The Company has commenced a national search for his successor

    $OMCL
    Computer Manufacturing
    Technology
  • Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

    Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. "We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year," stated Randall Lipps, ch

    $OMCL
    Computer Manufacturing
    Technology

$OMCL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OMCL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$OMCL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$OMCL
SEC Filings

See more

$OMCL
Leadership Updates

Live Leadership Updates

See more
  • Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

    The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

    $OMCL
    Computer Manufacturing
    Technology
  • Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

    FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me

    $CLOV
    $OMCL
    Medical Specialities
    Health Care
    Computer Manufacturing
    Technology
  • Omnicell Elects Eileen Voynick to Board of Directors

    Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e

    $MDRX
    $OMCL
    $CDK
    EDP Services
    Technology
    Computer Manufacturing
    Retail: Computer Software & Peripheral Equipment

$OMCL
Financials

Live finance-specific insights

See more
  • Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

    Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. "We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year," stated Randall Lipps, ch

    $OMCL
    Computer Manufacturing
    Technology
  • Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025

    Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the fourth quarter and full year 2024, before market open on Thursday, February 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 2515873. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-pr

    $OMCL
    Computer Manufacturing
    Technology
  • Omnicell Announces Third Quarter 2024 Results

    Omnicell delivers solid third quarter financial results Total revenues of $282 million GAAP net income per diluted share of $0.19 Non-GAAP net income per diluted share of $0.56 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its third quarter ended September 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased to deliver another consecutive quarter of solid financial performance, with results within or exceeding each of ou

    $OMCL
    Computer Manufacturing
    Technology

$OMCL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more